Navigation Links
WuXi PharmaTech Receives Award from BASF
Date:7/1/2009

SHANGHAI, July 1 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that it had received an award from BASF for excellent service and outstanding contributions in the area of custom synthesis for new crop-protection active ingredients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

"We had been looking for a good CRO collaboration partner for years, and today I think we have found one, a top-notch partner," Dr. Alfred Hackenberger, President of the Specialty Chemicals Research Division at BASF, commented at the award ceremony. "And I know that WuXi will continue to provide the same excellent service in the future."

"We are pleased to receive this award by BASF in recognition of the efforts of WuXi's talented team," commented Dr. Ge Li, Chairman and CEO of WuXi AppTec. "We will continue to focus on customer service to earn the trust and support of our partners."

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, we provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners to improve the success of research and shorten the time of development cost effectively in discovering and developing drugs and medical devices.

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 2016 According to the ... Products (Consumable, Instruments, Automated Cell Expansion System), Cells ... Cell Research, Cancer, and Cell-Based Research), End-users (Biopharmaceutical ... Global Revenue, Trends, Growth, Share, Size and Forecast ... global cell expansion market is expected to reach ...
(Date:12/5/2016)... WOODCLIFF LAKE, N.J. , Dec. 5, 2016 ... its Phase 3 open-label two-year study of rufinamide, ... of the American Epilepsy Society (AES) held from ... . Analysis of final two-year safety, tolerability and ... therapy with rufinamide experienced similar safety and tolerability ...
(Date:12/4/2016)... (PRWEB) , ... December 03, 2016 , ... ... ground-breaking microbiome studies. A microbiome impact grant award has been made to Dr. ... of heavy smoking and drinking on the oral microbiome. Grant proposals have been ...
(Date:12/2/2016)... 2016 More than $4.3 million was raised last ... DHMD ). The gala was held at the American Museum ... and honored Alan Alda and ... and medicine and the public understanding of science. Since the ... event has raised $40 million for the Laboratory,s research and ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
Breaking Biology News(10 mins):